+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (ScrHSA, OsrHSA), By Application (Cell Culture Media, Medical Supplements, Other Applications), By End User (Biopharmaceutical Companies, Academic & Research Institutes, CROs / CMOs), By Expression System (Rice-Based, Yeast-Based, Other Expression Systems), By Product Form (Lyophilized Powder, Liquid Solution), and Regional Forecast, 2026-2034
The global recombinant human serum albumin market was valued at USD 83.7 million in 2025 and is estimated at USD 90.0 million in 2026. The market is projected to reach USD 160.1 million by 2034, representing a 7.5% CAGR during 2026–2034.
Recombinant human serum albumin is a non-plasma-derived alternative to human serum albumin used as a stabilizer, carrier, excipient and cell-culture supplement across biopharmaceutical manufacturing, cell and gene therapy, vaccines, diagnostics and research. Commercial value is driven by the ability to provide a defined albumin source while reducing reliance on human plasma and animal-derived components.
Cell-culture media is the largest application in the syndicated market structure, accounting for 73% of 2025 revenue. Demand is supported by biologics manufacturing, viral-vector production, stem-cell and cell-therapy workflows, vaccine formulation and research systems where consistency, traceability and freedom from animal- or human-derived contaminants are important procurement criteria.
The market is also shifting from lyophilized material toward ready-to-use high-concentration liquid formats. InVitria launched Optibumin 25 in February 2025 as a sterile 25% w/v recombinant human serum albumin solution for bioprocessing and cell/gene therapy applications. Sartorius continues to position Recombumin as a cGMP recombinant albumin produced in yeast and notes use in licensed vaccines with more than 200 million administered doses since 2006, demonstrating that recombinant albumin has moved well beyond research-only use.
Source: Sartorius Recombumin; InVitria recombinant HSA; InVitria Optibumin 25 launch; FUJIFILM Wako rHSA.
The study defines the global recombinant human serum albumin market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | ScrHSA; OsrHSA |
| By Application | Cell Culture Media; Medical Supplements; Other Applications |
| By End User | Biopharmaceutical Companies; Academic & Research Institutes; CROs / CMOs |
| By Expression System | Rice-Based; Yeast-Based; Other Expression Systems |
| By Product Form | Lyophilized Powder; Liquid Solution |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; France; Switzerland; China; Japan; India; South Korea; Australia; Brazil; GCC countries and other major markets |
| Key Market Players | Sartorius (Albumedix / Recombumin); Merck KGaA; InVitria; Thermo Fisher Scientific; FUJIFILM Irvine Scientific; FUJIFILM Wako Pure Chemical; Takara Bio; Cytiva; Lonza; HiMedia Laboratories; Oryzogen; NCPC |
The market includes recombinant human serum albumin produced through non-plasma expression systems and sold for bioprocessing, pharmaceutical, cell-culture, diagnostic, research and selected therapeutic-support applications. Revenue is attributed to recombinant albumin products rather than conventional plasma-derived human serum albumin.
Plasma-derived albumin, bovine serum albumin and unrelated recombinant proteins are outside the core market. Finished biologic or cell-therapy product revenue is not attributed to the rHSA market; only the recombinant albumin raw material or formulated albumin input is included.
Cell-culture media accounts for 73% of 2025 market revenue in the syndicated model. Recombinant albumin is used to stabilize cells, proteins and process intermediates while providing a defined alternative to plasma-derived or animal-derived albumin in regulated bioprocessing.
Cell and gene therapy developers increasingly scrutinize raw-material origin, viral safety, lot consistency and regulatory traceability. Recombinant albumin produced in yeast, rice or other controlled expression systems can reduce biological-source variability and simplify risk assessment compared with plasma-derived materials.
Sartorius states that Recombumin is produced in Saccharomyces cerevisiae under cGMP controls and has been used in licensed vaccines, with more than 200 million doses administered since 2006. This track record strengthens confidence in recombinant albumin as a regulated pharmaceutical excipient rather than a research-only reagent.
Recombinant albumin requires controlled expression, purification, analytical characterization and quality documentation. In cost-sensitive culture and laboratory applications, bovine serum albumin or other protein supplements can remain economically attractive, so rHSA adoption is strongest where safety, consistency or regulatory requirements justify the premium.
Ready-to-use sterile liquid rHSA can eliminate reconstitution steps and reduce handling risk in closed bioprocessing. InVitria’s Optibumin 25 launch illustrates the shift toward formats designed for direct integration into cell and gene therapy, biologic and diagnostic manufacturing workflows.
Source: Sartorius recombinant HSA; InVitria Optibumin 25; InVitria launch.
Recombinant albumin is increasingly positioned for cell preservation, expansion, cryopreservation, viral-vector production and final-formulation workflows. These applications place a premium on cGMP quality, animal-origin-free sourcing and consistent performance because raw-material variability can directly affect advanced-therapy manufacturing.
InVitria presented 2026 data on recombinant HSA for lentiviral-vector manufacturing, highlighting the role of albumin in vector yield and process robustness. Growing gene-therapy pipelines can therefore create demand beyond traditional cell-culture supplementation.
Lyophilized recombinant albumin remains widely used because of storage and handling familiarity, but concentrated sterile liquids can simplify closed-system manufacturing and reduce preparation time. The commercial shift favors suppliers that can provide both formats with strong stability and documentation packages.
InVitria published 2026 application work on recombinant albumin for diagnostic immunoassays, broadening the addressable market beyond biopharmaceutical manufacturing. Diagnostic use values consistent protein background, low contaminant burden and reliable assay performance.
Albumedix is now part of Sartorius, combining specialized recombinant albumin expertise with a global bioprocessing platform. This raises competitive expectations around supply continuity, global technical support and integration with broader cell-culture and advanced-therapy workflows.
Source: InVitria ASGCT 2026; InVitria diagnostic application; Sartorius Recombumin.
rHSA product differentiation is determined by expression system, purity, post-translational consistency, endotoxin and contaminant control, product form and the documentation required for regulated biomanufacturing.
Yeast-based systems provide established fermentation infrastructure and are used for commercial recombinant albumin such as Recombumin. Their strength is scalable production with well-characterized process controls.
Rice-based expression offers a non-animal production route and is used by suppliers serving cell culture and research applications. It can provide high-volume protein expression without human plasma sourcing.
Powder products remain important where shelf stability, transport efficiency and flexible final concentration are priorities. Users trade this flexibility against the need for controlled reconstitution.
Sterile concentrated liquid rHSA reduces preparation steps and can fit closed manufacturing workflows. The format is particularly attractive for cell and gene therapy and other high-value processes.
Source: Sartorius; InVitria; FUJIFILM Wako.
Type segmentation distinguishes recombinant albumin products by the report’s commercial product classifications. ScrHSA is the dominant type in the syndicated model and accounted for 91% of 2025 revenue.
ScrHSA is the leading type, representing 91% of 2025 market revenue in the report model. Its commercial strength reflects established use in cell culture, vaccine and bioprocess applications where defined recombinant albumin is valued for consistency and absence of plasma sourcing.
OsrHSA represents a smaller segment serving specialized culture, formulation and research applications. Growth depends on supplier qualification, expression-system economics and the ability to demonstrate comparable or improved performance versus established rHSA products.
Application demand is concentrated in cell-culture and bioprocessing workflows, with additional use in medical supplements, formulation support, diagnostics and research.
Cell-culture media is the leading application with 73% of 2025 revenue. Recombinant albumin supports cell growth, stabilizes sensitive molecules and replaces plasma-derived or animal-derived proteins in defined media and advanced-therapy workflows.
Medical-supplement applications use recombinant albumin where high purity, biological compatibility and controlled sourcing are required. Adoption is more selective because cost and regulatory qualification can be higher than for conventional albumin sources.
Other uses include vaccine stabilization, diagnostic assays, protein formulation, cryopreservation, viral-vector manufacturing and research. These smaller applications can command high value per unit because product quality and technical documentation are critical.
End-user purchasing behavior is determined by regulatory burden, process scale and whether recombinant albumin is used in commercial manufacturing or exploratory research.
Biopharmaceutical companies are the most commercially important end users because they purchase qualified rHSA for biologics, vaccines, advanced therapies and process development. Long-term supply, change control and regulatory support are central purchasing criteria.
Academic laboratories use rHSA in cell culture, stem-cell research, assay development and translational science. Volumes are smaller, but research adoption can seed future commercial applications.
Contract research and manufacturing organizations use rHSA across client programs and require flexible formats, documented quality and dependable supply. Multi-client operations can accelerate qualification of products that perform consistently across different processes.
Expression-system choice affects production scale, impurity profile, cost structure and customer perception of biological-source risk.
Rice-based expression provides a plant-derived production route and is used in commercial rHSA products for cell culture and laboratory applications. The system avoids human plasma and animal components, supporting defined-material strategies.
Yeast-based production is a leading commercial route because fermentation is scalable and well established. Sartorius Recombumin is produced in Saccharomyces cerevisiae and supported by pharmaceutical-grade quality documentation.
Other systems include bacterial and alternative recombinant platforms. Their commercial position depends on expression yield, folding, purity, downstream processing and the ability to meet application-specific regulatory requirements.
Product form is increasingly important as customers seek to reduce handling steps in regulated manufacturing.
Lyophilized rHSA offers storage stability and concentration flexibility and remains important across research and bioprocess applications. Reconstitution adds an operator step but allows users to prepare application-specific concentrations.
Liquid rHSA is gaining importance in closed and high-throughput workflows because it can be supplied sterile and ready for direct addition. Concentrated formats can reduce preparation time and support more standardized manufacturing.
Regional demand follows biotechnology manufacturing intensity, advanced-therapy investment, recombinant-protein capacity and the willingness of manufacturers to qualify premium animal-origin-free raw materials. North America leads consumption, while Asia-Pacific combines growing use with expanding production capability.
North America accounted for 59% of 2025 consumption in the syndicated model. The United States anchors demand through a dense biopharmaceutical, vaccine, cell and gene therapy and diagnostic-manufacturing ecosystem that values qualified recombinant raw materials.
Europe has strong recombinant-protein expertise and a mature biologics manufacturing base. Sartorius provides a major regional supply platform through the former Albumedix business and Recombumin portfolio, while European customers place strong emphasis on traceability and regulatory documentation.
Asia-Pacific combines established recombinant-protein manufacturing with rapid biopharmaceutical capacity growth. China, Japan, South Korea and India are expanding biologics and advanced-therapy ecosystems, increasing demand for qualified media supplements and stabilizers.
Demand is smaller and concentrated in vaccine, research and biopharmaceutical manufacturing centers. Adoption depends on import economics and whether regulated manufacturing programs justify premium recombinant inputs.
The regional market remains limited but can grow around biotechnology investment, vaccine manufacturing and research infrastructure. Demand is concentrated in higher-specification institutional and manufacturing settings rather than general laboratory use.
Source: Sartorius; InVitria; FUJIFILM Wako.
rHSA is often used upstream or as an excipient in regulated products, so commercial adoption depends on supplier quality systems, traceability, change control and documentation as much as on protein purity.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| cGMP manufacturing | Leading commercial rHSA products are manufactured under cGMP or comparable pharmaceutical-quality systems. | Supports qualification for biologics, vaccines and advanced therapies where raw-material control is scrutinized. |
| Animal-origin-free sourcing | Recombinant production can avoid plasma and animal-derived raw materials. | Reduces biological-source risk and supports defined-media and advanced-therapy manufacturing strategies. |
| Compendial and regulatory documentation | Sartorius states that Recombumin is USP-NF compliant and supported by pharmaceutical-grade documentation. | Creates a higher barrier to entry and strengthens the value of established suppliers in regulated applications. |
| Closed-system compatibility | Sterile liquid formats can be supplied for direct integration into bioprocessing systems. | Supports cell and gene therapy manufacturing by reducing open handling and preparation steps. |
Source: Sartorius Recombumin; InVitria Optibumin 25.
The rHSA market is specialized and relatively concentrated because customers require reproducible protein quality, validated expression systems and dependable regulatory support. Supplier differentiation centers on cGMP status, animal-origin-free claims, product form, purity, functional performance, global technical support and the ability to supply commercial-scale bioprocess customers.
Sartorius combines the Recombumin recombinant albumin portfolio with a broad cell-culture and advanced-therapy offering. Integration strengthens supply-chain reach and provides customers with a larger ecosystem of qualified process materials.
InVitria focuses on animal-free recombinant proteins and has expanded from lyophilized products into sterile high-concentration liquid rHSA. The company is positioning albumin across cell and gene therapy, viral vectors and diagnostics.
Large life-science suppliers compete through distribution reach, media and reagent portfolios, technical documentation and established relationships with biopharmaceutical manufacturers and research laboratories.
Source: Sartorius; InVitria; FUJIFILM Wako.
June 2026: InVitria published application data for Optibumin 25 in diagnostic immunoassays, extending commercial positioning of recombinant albumin beyond cell culture and advanced therapy into assay stabilization and diagnostic manufacturing.
May 2026: InVitria presented data on recombinant human serum albumin for lentiviral-vector manufacturing at ASGCT 2026, reinforcing viral-vector production as an emerging high-value use case.
April 2026: InVitria showcased Exbumin and Optibumin 25 at IPEC Excipient World and the Biologics Summit, highlighting use of recombinant albumin in on-market biologics and regulated biopharmaceutical workflows.
February 2025: InVitria launched Optibumin 25, a sterile 25% recombinant human serum albumin solution designed for bioprocessing and cell and gene therapy manufacturing.
Source: InVitria diagnostic application; InVitria ASGCT 2026; InVitria IPEC 2026; InVitria Optibumin launch.
The global recombinant human serum albumin market market is projected to grow from USD 90.0 million in 2026 to USD 160.1 million by 2034, at a 7.5% CAGR during 2026–2034. Growth is expected to be supported by biologics, vaccines, cell and gene therapy, viral-vector manufacturing and broader replacement of plasma- or animal-derived proteins in high-value processes. Pricing will remain disciplined in routine research applications, while regulated manufacturing and ready-to-use liquid formats can sustain premium growth.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Cell-culture demand | Cell-culture media represents 73% of the 2025 application mix. | Provides a broad recurring demand base tied to biopharmaceutical and research activity. |
| Advanced therapies | Cell and gene therapy workflows value defined, animal-origin-free and cGMP-qualified raw materials. | Raises the strategic value of rHSA in regulated high-growth manufacturing. |
| Liquid product formats | Sterile concentrated liquid rHSA reduces reconstitution and handling steps. | Creates premium opportunities in closed-system manufacturing. |
| Supplier quality requirements | Customers require traceability, change control, analytical characterization and dependable supply. | Supports market concentration around qualified suppliers and creates barriers to new entrants. |
| Asia-Pacific biomanufacturing | Biologics and advanced-therapy capacity is expanding across major Asian markets. | Broadens consumption and can support additional regional production. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global recombinant human serum albumin market landscape.
24LifeScience develops recombinant human serum albumin market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. Product and application evidence is checked against current primary supplier documentation. Corporate names are updated for ownership changes, including the integration of Albumedix into Sartorius, to avoid presenting acquired businesses as independent current competitors.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 83.7 million in 2025 and is estimated at USD 90.0 million in 2026. It is projected to reach USD 160.1 million by 2034 at a 7.5% CAGR during 2026–2034.
It is human albumin produced through a recombinant expression system rather than isolated from donated human plasma. It is used as a stabilizer, carrier, excipient and cell-culture supplement.
Cell-culture media is the leading application, accounting for 73% of 2025 market revenue in the syndicated model.
North America is the largest consumption market with 59% of 2025 global demand in the syndicated model.
rHSA provides a defined protein source that can be animal-origin-free and plasma-free, supporting consistency, traceability and biological-source risk management in regulated manufacturing.
Commercial recombinant albumin is produced using systems including yeast and rice, with other recombinant platforms also represented in the market.
The market includes lyophilized powders and liquid solutions. Concentrated sterile liquid formats are gaining importance for closed bioprocessing and advanced-therapy workflows.
The study profiles Sartorius through its Albumedix/Recombumin business, Merck, InVitria, Thermo Fisher Scientific, FUJIFILM, Takara Bio, Cytiva, Lonza, HiMedia, Oryzogen and NCPC.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
